Health Ongoing Trials Enhance Use of CDK4/6 Inhibitors in Breast Cancer The use of CDK4/6 inhibitors remains pivotal in treating hormone receptor (HR)-positive metastatic breast cancer, both HER2-negative and HER2-positive, especially for patients experiencing visceral... Editorial1 day ago